Treatment of Philadelphia Chromosome (BCR::ABL1)-Positive Acute Lymphoblastic Leukemia
This protocol addresses acute lymphoblastic leukemia in patients carrying the Philadelphia chromosome (BCR::ABL1 fusion) — a high-risk molecular subtype that requires a specific treatment approach distinct from Ph-negative ALL.
Clinical scenario
Philadelphia chromosome / BCR::ABL1-positive ALL, confirmed by karyotyping and/or molecular genetics.
Treatment approach (partial overview)
The management of Ph+ ALL involves a transplant-based strategy as a central element of care. The complete protocol — full regimen, sequencing, and decision criteria — is available in the structured reference below.
References
- Confirmation of Ph+ ALL relies on karyotyping and/or molecular genetics.
- SCT was associated with significant OS benefit in patients treated with imatinib and chemotherapy and therefore remains SoC.
DOI: 10.1182/blood.2023023568
View source ↗